Business context and reporting period
Grifols, S.A. filed this audited Form 20-F for the fiscal year ended December 31, 2020. It is an annual report, not a standalone fourth-quarter filing; the supplied filing text does not provide separate Q4 results. Financial statements are prepared under IFRS as issued by the IASB and presented in euros.
Grifols is a vertically integrated plasma-derived medicines, diagnostics and hospital-products company. Bioscience generated about 79.5% of 2020 revenue; the United States and Canada accounted for 67.4%.
Key financial metrics
| Metric | FY 2020 | FY 2019 | Change/comment |
|---|---|---|---|
| Net revenue | €5.340bn | €5.099bn | +4.7% reported; +6.1% at constant currency |
| Gross profit / margin | €2.255bn / 42.2% | €2.341bn / 45.9% | Margin down 3.7 percentage points |
| Operating result | €996m | €1.131bn | Down 12.0% |
| Profit before tax | €879m | €817m | Up 7.5% |
| Consolidated profit | €709m | €649m | Up 9.3% |
| Profit attributable to Grifols shareholders | €619m | €625m | Down 1.1%; EPS €0.90 vs. €0.91 |
| Operating cash flow | €1.110bn | €569m | Increased substantially, including from lower inventories |
| Investing / financing cash flow | (€858m) / (€354m) | (€549m) / (€332m) | Investing outflow included acquisitions and capital spending |
| Cash and cash equivalents | €580m | €742m | Down €162m |
| Financial liabilities | €7.027bn | €7.207bn | Balance-sheet carrying amounts, including lease liabilities |
At year-end, Grifols reported approximately €922.6m of available credit facilities, including €817.4m of undrawn revolving commitments. Management described cash plus available facilities as liquidity of close to €1.5bn. Total current liabilities were €1.335bn and current assets €3.165bn.
Material changes versus the prior comparable period
- Revenue growth was led by Bioscience (+6.2%) and Diagnostic (+5.8%); Hospital revenue fell 11.7% and Bio Supplies fell 15.9%.
- Cost of sales rose 11.9%, faster than revenue. Management attributed the margin decline principally to a €205m inventory-value adjustment associated mainly with COVID-19 effects.
- Operating expenses rose 5.0%, including higher R&D spending (€294m, up 6.6%). Management said a COVID-related expense-containment plan contributed €112m of benefit without reducing the workforce or innovation investment.
- Finance result improved to a €178m expense from €275m, supported by lower financing costs after the 2019 refinancing and positive fair-value/foreign-exchange items. The Shanghai RAAS transaction included a €56.5m fair-value gain; equity-accounted investees contributed €60.2m to profit versus a €39.5m loss in 2019.
- Profit attributable to the parent declined slightly despite higher consolidated profit, as profit attributable to non-controlling interests increased to €90m from €23m.
- Other comprehensive income was affected by €747m of negative translation differences; total comprehensive income was negative €17m, compared with positive €677m in 2019.
Outlook, management commentary, risks and unusual items
- COVID-19 and plasma: Plasma collections were approximately 15% lower in 2020. Management expected collection levels to begin recovering in the second half of 2021, while noting timing and pace were uncertain. The company reported operations remained open and estimated a net €155m adverse operating-result impact from the pandemic.
- Capacity and investment: Grifols cited a €1.4bn 2018–2022 investment plan, plans for approximately 21m liters of fractionation capacity by 2022 and 28m by 2026, and a target of 435 approved plasma centers globally by 2025. These are plans, not guarantees.
- Market outlook: Management cited expected long-term industry sales growth of 6%–7% annually and continuing demand for plasma-derived therapies. It did not provide a clear company-specific FY2021 revenue or earnings forecast in the supplied text.
- Acquisitions and expansion: In 2020 Grifols acquired GC Pharma’s Montreal facilities and 11 U.S. plasma centers for $457m, acquired full ownership of Alkahest, and exchanged a 45% economic interest in its U.S. diagnostics subsidiary for a 26.2% stake in Shanghai RAAS. Subsequent to year-end, it acquired the remaining GigaGen shares and 25 U.S. plasma centers from BPL for $382m, both intended to be funded with company resources.
- Leverage and rates: The company reported substantial indebtedness, debt covenants, pledged collateral and exposure to variable rates and foreign exchange. Approximately 53.9% of senior interest-bearing debt was variable-rate; a 100-basis-point rate increase was estimated to raise 2020 interest expense by €36.2m. A 10% stronger U.S. dollar was estimated to increase equity by €751m and profit by €13m, assuming other variables remained constant.
- Other key risks: Plasma supply and collection-center disruption, manufacturing contamination or yield variability, product safety and regulatory compliance, competition and pricing/reimbursement pressures, foreign-exchange movements, and execution of large capital projects. Goodwill was €5.332bn; the auditor identified the Diagnostic cash-generating unit goodwill impairment assessment as a critical audit matter, with €2.433bn of Diagnostic goodwill.
- Contingencies and audit: The filing describes ordinary-course litigation and an ongoing Abbott royalty/patent dispute; an arbitration award of $4m was made to GDS/Ortho, while court proceedings continued. KPMG issued unqualified opinions on the financial statements and internal control over financial reporting; management also reported effective disclosure controls and financial reporting controls.
Important facts an investor should verify
- Confirm the separate Q4 2020 performance from quarterly disclosures; this 20-F reports annual results, not standalone fourth-quarter figures.
- Assess whether plasma collections recover as expected and whether the 2020 inventory adjustment, higher plasma costs and lower capacity utilization continue to affect margins.
- Reconcile debt measures, maturities, covenant headroom and liquidity availability, including lease liabilities and the variable-rate exposure.
- Track delivery, regulatory approvals and returns from the Montreal, Clayton, Dublin and other capacity projects, as well as the stated collection-center and fractionation targets.
- Review Diagnostic goodwill impairment assumptions and sensitivities, and the financial contribution and funding needs of acquisitions and equity-accounted investments.
- Monitor the Abbott and Siemens disputes, regulatory developments, product-safety matters, and the effect of pricing and reimbursement pressure on key immunoglobulin products.